A responsible CBD market: Closing the gaps in testing and supply chains

September 5, 2019
Volume: 
22
Issue: 
7

The 2018 Farm Bill removed hemp and hemp-derived cannabidiol (CBD) from the U.S. Drug Enforcement Administration’s Schedule I drug list, but even so, there’s still much uncertainty around how the resulting CBD marketplace will be regulated and to what extent existing rules and best practices will be enforced. In the meantime, responsible parties aren’t waiting for standards to come from above. A growing faction of industry associations, testing labs, suppliers, and finished product manufacturers are exercising due diligence, each in their own way, to self-regulate and promote responsible behavior, claims, and best practices in an immature hemp and CBD market. Here’s a snapshot of their progress.

 

Photo © AdobeStock.com/Elroi